Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Onconetix (ONCO) Research & Development (2023 - 2025)

Historic Research & Development for Onconetix (ONCO) over the last 3 years, with Q3 2025 value amounting to -$3211.0.

  • Onconetix's Research & Development fell 10293.6% to -$3211.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$90716.0, marking a year-over-year decrease of 10490.6%. This contributed to the annual value of $154359.0 for FY2024, which is 9208.17% down from last year.
  • Per Onconetix's latest filing, its Research & Development stood at -$3211.0 for Q3 2025, which was down 10293.6% from -$111670.0 recorded in Q2 2025.
  • Onconetix's 5-year Research & Development high stood at $1.1 million for Q1 2023, and its period low was -$198921.0 during Q4 2023.
  • Moreover, its 3-year median value for Research & Development was $24455.0 (2025), whereas its average is $183030.9.
  • As far as peak fluctuations go, Onconetix's Research & Development soared by 9985.42% in 2024, and later crashed by 293451.09% in 2025.
  • Over the past 3 years, Onconetix's Research & Development (Quarter) stood at -$198921.0 in 2023, then soared by 99.85% to -$290.0 in 2024, then plummeted by 1007.24% to -$3211.0 in 2025.
  • Its Research & Development was -$3211.0 in Q3 2025, compared to -$111670.0 in Q2 2025 and $24455.0 in Q1 2025.